Henderson J D, White G L
Department of Physician Assistant Studies, College of Allied Health Professions, University of South Alabama, Mobile 36604, USA.
Mil Med. 1998 Apr;163(4):193-7.
The regulatory aspects of generic drug substitution and the scientific concepts that serve as the basis for generic drug approval are discussed, with emphasis on the source of therapeutic equivalence information compiled by the Food and Drug Administration in Approved Drug Products with Therapeutic Equivalence Evaluations. The Food and Drug Administration's determination of bioequivalence for immediate-release and extended-release dosage forms is summarized, with a discussion of the underlying assumptions and current issues regarding bioequivalence testing. Medical practitioners must comply with the regulations stated in each state's Pharmacy Practice Act when allowing generic substitution and should ensure that the substituted product is therapeutically equivalent to the prescribed product.
本文讨论了仿制药替代的监管方面以及作为仿制药批准基础的科学概念,重点是美国食品药品监督管理局(FDA)在《有治疗等效性评估的已批准药品》中汇编的治疗等效性信息的来源。总结了FDA对速释和缓释剂型生物等效性的判定,并讨论了生物等效性测试的基本假设和当前问题。医生在允许仿制药替代时必须遵守每个州《药房实践法》规定的法规,并应确保替代产品在治疗上等同于处方产品。